In Vitro Activities of Tigecycline in Combination with Amikacin or Colistin Against Carbapenem-Resistant Acinetobacter baumannii
Carbapenem-resistant Acinetobacter baumannii (CRAB) has been a common pathogen of nosocomial infections and severely threatened the public health for decades. Tigecycline is a new type of antibacterial glycylcycline and minocycline derivative and has been used to treat CRAB in clinical practice. How...
Gespeichert in:
| Veröffentlicht in: | Applied biochemistry and biotechnology 2021-12, Vol.193 (12), p.3867-3876 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3876 |
|---|---|
| container_issue | 12 |
| container_start_page | 3867 |
| container_title | Applied biochemistry and biotechnology |
| container_volume | 193 |
| creator | Wu, Hongbin Feng, Heqiang He, Lijie Zhang, Heping Xu, Ping |
| description | Carbapenem-resistant
Acinetobacter baumannii
(CRAB) has been a common pathogen of nosocomial infections and severely threatened the public health for decades. Tigecycline is a new type of antibacterial glycylcycline and minocycline derivative and has been used to treat CRAB in clinical practice. However, the synergistic effects of tigecycline in combination with other antibiotics including colistin or amikacin remain unclear. A total of 216 CRAB isolates were collected from multiple body parts of different patients. The gene types of these isolates were analyzed and their resistance to carbapenems was determined by Etest. Broth microdilution method was utilized to evaluate the minimum inhibitory concentration (MIC) of each sample. Checkerboard screening technique was performed to demonstrate the synergistic effects of antibiotics and fractional inhibitory concentration index (FICI) was established. Therefore, the joint treatment of tigecycline and colistin (1:1) could effectively improve the sensitivity of AB to antibiotics. OXA-24-like isolates were more sensitive to the combination of tigecycline and amikacin. On the other hand, OXA-23-like isolates were more sensitive to the combination of tigecycline and colistin. Tigecycline exhibited synergistic effects with amikacin and colistin to inhibit CRAB. |
| doi_str_mv | 10.1007/s12010-021-03664-z |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2572932913</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2601154852</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-e9880e002393abb40b588ce508d04bbe108dfbccb0e38f40b082e6b5e66b0e683</originalsourceid><addsrcrecordid>eNp9kUFv1DAQha0K1C6FP8ChssSFS2Bsx4lzXK0KVKqEhNpeLdudLC6JvbWdVu2Jn45hC0gcOM1o3jfP1jxCXjN4xwD695lxYNAAZw2IrmubxwOyYlIOdTSwZ2QFvBcN52o4Ii9yvgFgXMn-kByJVvK2E2JFvp8FeuVLinTtir_zxWOmcaQXfovuwU0-IPWBbuJsfTDFx0DvfflK17P_ZlxVYqri5HOp_XprfMiFbkyyZocB5-YL5qqZUKp_9SrRGlcwUWuW2YTg_UvyfDRTxldP9Zhcfji92Hxqzj9_PNuszxsnelkaHJQCBOBiEMbaFqxUyqEEdQ2ttchqM1rnLKBQY5VBceysxK6ro06JY_J277tL8XbBXPTss8NpMgHjkjWXPR9EvZuo6Jt_0Ju4pFB_p3kHjMlWSV4pvqdcijknHPUu-dmkB81A_8xH7_PRNR_9Kx_9WJdOnqwXO-P1n5XfgVRA7IFcpbDF9Pft_9j-AFmGnQM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2601154852</pqid></control><display><type>article</type><title>In Vitro Activities of Tigecycline in Combination with Amikacin or Colistin Against Carbapenem-Resistant Acinetobacter baumannii</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Wu, Hongbin ; Feng, Heqiang ; He, Lijie ; Zhang, Heping ; Xu, Ping</creator><creatorcontrib>Wu, Hongbin ; Feng, Heqiang ; He, Lijie ; Zhang, Heping ; Xu, Ping</creatorcontrib><description>Carbapenem-resistant
Acinetobacter baumannii
(CRAB) has been a common pathogen of nosocomial infections and severely threatened the public health for decades. Tigecycline is a new type of antibacterial glycylcycline and minocycline derivative and has been used to treat CRAB in clinical practice. However, the synergistic effects of tigecycline in combination with other antibiotics including colistin or amikacin remain unclear. A total of 216 CRAB isolates were collected from multiple body parts of different patients. The gene types of these isolates were analyzed and their resistance to carbapenems was determined by Etest. Broth microdilution method was utilized to evaluate the minimum inhibitory concentration (MIC) of each sample. Checkerboard screening technique was performed to demonstrate the synergistic effects of antibiotics and fractional inhibitory concentration index (FICI) was established. Therefore, the joint treatment of tigecycline and colistin (1:1) could effectively improve the sensitivity of AB to antibiotics. OXA-24-like isolates were more sensitive to the combination of tigecycline and amikacin. On the other hand, OXA-23-like isolates were more sensitive to the combination of tigecycline and colistin. Tigecycline exhibited synergistic effects with amikacin and colistin to inhibit CRAB.</description><identifier>ISSN: 0273-2289</identifier><identifier>EISSN: 1559-0291</identifier><identifier>DOI: 10.1007/s12010-021-03664-z</identifier><identifier>PMID: 34524633</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Acinetobacter baumannii ; Acinetobacter baumannii - growth & development ; Amikacin ; Amikacin - agonists ; Amikacin - pharmacology ; Antibiotics ; Antiinfectives and antibacterials ; beta-Lactam Resistance - drug effects ; Biochemistry ; Biotechnology ; Body parts ; Carbapenems ; Chemistry ; Chemistry and Materials Science ; Colistin ; Colistin - agonists ; Colistin - pharmacology ; Drug Resistance, Multiple, Bacterial - drug effects ; Drug Synergism ; Minimum inhibitory concentration ; Minocycline ; Nosocomial infection ; Original Article ; Public health ; Synergistic effect ; Tigecycline ; Tigecycline - agonists ; Tigecycline - pharmacology</subject><ispartof>Applied biochemistry and biotechnology, 2021-12, Vol.193 (12), p.3867-3876</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021</rights><rights>2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</rights><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-e9880e002393abb40b588ce508d04bbe108dfbccb0e38f40b082e6b5e66b0e683</citedby><cites>FETCH-LOGICAL-c375t-e9880e002393abb40b588ce508d04bbe108dfbccb0e38f40b082e6b5e66b0e683</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12010-021-03664-z$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12010-021-03664-z$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34524633$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wu, Hongbin</creatorcontrib><creatorcontrib>Feng, Heqiang</creatorcontrib><creatorcontrib>He, Lijie</creatorcontrib><creatorcontrib>Zhang, Heping</creatorcontrib><creatorcontrib>Xu, Ping</creatorcontrib><title>In Vitro Activities of Tigecycline in Combination with Amikacin or Colistin Against Carbapenem-Resistant Acinetobacter baumannii</title><title>Applied biochemistry and biotechnology</title><addtitle>Appl Biochem Biotechnol</addtitle><addtitle>Appl Biochem Biotechnol</addtitle><description>Carbapenem-resistant
Acinetobacter baumannii
(CRAB) has been a common pathogen of nosocomial infections and severely threatened the public health for decades. Tigecycline is a new type of antibacterial glycylcycline and minocycline derivative and has been used to treat CRAB in clinical practice. However, the synergistic effects of tigecycline in combination with other antibiotics including colistin or amikacin remain unclear. A total of 216 CRAB isolates were collected from multiple body parts of different patients. The gene types of these isolates were analyzed and their resistance to carbapenems was determined by Etest. Broth microdilution method was utilized to evaluate the minimum inhibitory concentration (MIC) of each sample. Checkerboard screening technique was performed to demonstrate the synergistic effects of antibiotics and fractional inhibitory concentration index (FICI) was established. Therefore, the joint treatment of tigecycline and colistin (1:1) could effectively improve the sensitivity of AB to antibiotics. OXA-24-like isolates were more sensitive to the combination of tigecycline and amikacin. On the other hand, OXA-23-like isolates were more sensitive to the combination of tigecycline and colistin. Tigecycline exhibited synergistic effects with amikacin and colistin to inhibit CRAB.</description><subject>Acinetobacter baumannii</subject><subject>Acinetobacter baumannii - growth & development</subject><subject>Amikacin</subject><subject>Amikacin - agonists</subject><subject>Amikacin - pharmacology</subject><subject>Antibiotics</subject><subject>Antiinfectives and antibacterials</subject><subject>beta-Lactam Resistance - drug effects</subject><subject>Biochemistry</subject><subject>Biotechnology</subject><subject>Body parts</subject><subject>Carbapenems</subject><subject>Chemistry</subject><subject>Chemistry and Materials Science</subject><subject>Colistin</subject><subject>Colistin - agonists</subject><subject>Colistin - pharmacology</subject><subject>Drug Resistance, Multiple, Bacterial - drug effects</subject><subject>Drug Synergism</subject><subject>Minimum inhibitory concentration</subject><subject>Minocycline</subject><subject>Nosocomial infection</subject><subject>Original Article</subject><subject>Public health</subject><subject>Synergistic effect</subject><subject>Tigecycline</subject><subject>Tigecycline - agonists</subject><subject>Tigecycline - pharmacology</subject><issn>0273-2289</issn><issn>1559-0291</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kUFv1DAQha0K1C6FP8ChssSFS2Bsx4lzXK0KVKqEhNpeLdudLC6JvbWdVu2Jn45hC0gcOM1o3jfP1jxCXjN4xwD695lxYNAAZw2IrmubxwOyYlIOdTSwZ2QFvBcN52o4Ii9yvgFgXMn-kByJVvK2E2JFvp8FeuVLinTtir_zxWOmcaQXfovuwU0-IPWBbuJsfTDFx0DvfflK17P_ZlxVYqri5HOp_XprfMiFbkyyZocB5-YL5qqZUKp_9SrRGlcwUWuW2YTg_UvyfDRTxldP9Zhcfji92Hxqzj9_PNuszxsnelkaHJQCBOBiEMbaFqxUyqEEdQ2ttchqM1rnLKBQY5VBceysxK6ro06JY_J277tL8XbBXPTss8NpMgHjkjWXPR9EvZuo6Jt_0Ju4pFB_p3kHjMlWSV4pvqdcijknHPUu-dmkB81A_8xH7_PRNR_9Kx_9WJdOnqwXO-P1n5XfgVRA7IFcpbDF9Pft_9j-AFmGnQM</recordid><startdate>20211201</startdate><enddate>20211201</enddate><creator>Wu, Hongbin</creator><creator>Feng, Heqiang</creator><creator>He, Lijie</creator><creator>Zhang, Heping</creator><creator>Xu, Ping</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7ST</scope><scope>7T7</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>RC3</scope><scope>SOI</scope><scope>7X8</scope></search><sort><creationdate>20211201</creationdate><title>In Vitro Activities of Tigecycline in Combination with Amikacin or Colistin Against Carbapenem-Resistant Acinetobacter baumannii</title><author>Wu, Hongbin ; Feng, Heqiang ; He, Lijie ; Zhang, Heping ; Xu, Ping</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-e9880e002393abb40b588ce508d04bbe108dfbccb0e38f40b082e6b5e66b0e683</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Acinetobacter baumannii</topic><topic>Acinetobacter baumannii - growth & development</topic><topic>Amikacin</topic><topic>Amikacin - agonists</topic><topic>Amikacin - pharmacology</topic><topic>Antibiotics</topic><topic>Antiinfectives and antibacterials</topic><topic>beta-Lactam Resistance - drug effects</topic><topic>Biochemistry</topic><topic>Biotechnology</topic><topic>Body parts</topic><topic>Carbapenems</topic><topic>Chemistry</topic><topic>Chemistry and Materials Science</topic><topic>Colistin</topic><topic>Colistin - agonists</topic><topic>Colistin - pharmacology</topic><topic>Drug Resistance, Multiple, Bacterial - drug effects</topic><topic>Drug Synergism</topic><topic>Minimum inhibitory concentration</topic><topic>Minocycline</topic><topic>Nosocomial infection</topic><topic>Original Article</topic><topic>Public health</topic><topic>Synergistic effect</topic><topic>Tigecycline</topic><topic>Tigecycline - agonists</topic><topic>Tigecycline - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wu, Hongbin</creatorcontrib><creatorcontrib>Feng, Heqiang</creatorcontrib><creatorcontrib>He, Lijie</creatorcontrib><creatorcontrib>Zhang, Heping</creatorcontrib><creatorcontrib>Xu, Ping</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Environment Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>Environment Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Applied biochemistry and biotechnology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wu, Hongbin</au><au>Feng, Heqiang</au><au>He, Lijie</au><au>Zhang, Heping</au><au>Xu, Ping</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In Vitro Activities of Tigecycline in Combination with Amikacin or Colistin Against Carbapenem-Resistant Acinetobacter baumannii</atitle><jtitle>Applied biochemistry and biotechnology</jtitle><stitle>Appl Biochem Biotechnol</stitle><addtitle>Appl Biochem Biotechnol</addtitle><date>2021-12-01</date><risdate>2021</risdate><volume>193</volume><issue>12</issue><spage>3867</spage><epage>3876</epage><pages>3867-3876</pages><issn>0273-2289</issn><eissn>1559-0291</eissn><abstract>Carbapenem-resistant
Acinetobacter baumannii
(CRAB) has been a common pathogen of nosocomial infections and severely threatened the public health for decades. Tigecycline is a new type of antibacterial glycylcycline and minocycline derivative and has been used to treat CRAB in clinical practice. However, the synergistic effects of tigecycline in combination with other antibiotics including colistin or amikacin remain unclear. A total of 216 CRAB isolates were collected from multiple body parts of different patients. The gene types of these isolates were analyzed and their resistance to carbapenems was determined by Etest. Broth microdilution method was utilized to evaluate the minimum inhibitory concentration (MIC) of each sample. Checkerboard screening technique was performed to demonstrate the synergistic effects of antibiotics and fractional inhibitory concentration index (FICI) was established. Therefore, the joint treatment of tigecycline and colistin (1:1) could effectively improve the sensitivity of AB to antibiotics. OXA-24-like isolates were more sensitive to the combination of tigecycline and amikacin. On the other hand, OXA-23-like isolates were more sensitive to the combination of tigecycline and colistin. Tigecycline exhibited synergistic effects with amikacin and colistin to inhibit CRAB.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>34524633</pmid><doi>10.1007/s12010-021-03664-z</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0273-2289 |
| ispartof | Applied biochemistry and biotechnology, 2021-12, Vol.193 (12), p.3867-3876 |
| issn | 0273-2289 1559-0291 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2572932913 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Acinetobacter baumannii Acinetobacter baumannii - growth & development Amikacin Amikacin - agonists Amikacin - pharmacology Antibiotics Antiinfectives and antibacterials beta-Lactam Resistance - drug effects Biochemistry Biotechnology Body parts Carbapenems Chemistry Chemistry and Materials Science Colistin Colistin - agonists Colistin - pharmacology Drug Resistance, Multiple, Bacterial - drug effects Drug Synergism Minimum inhibitory concentration Minocycline Nosocomial infection Original Article Public health Synergistic effect Tigecycline Tigecycline - agonists Tigecycline - pharmacology |
| title | In Vitro Activities of Tigecycline in Combination with Amikacin or Colistin Against Carbapenem-Resistant Acinetobacter baumannii |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T22%3A58%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20Vitro%20Activities%20of%20Tigecycline%20in%20Combination%20with%20Amikacin%20or%20Colistin%20Against%20Carbapenem-Resistant%20Acinetobacter%20baumannii&rft.jtitle=Applied%20biochemistry%20and%20biotechnology&rft.au=Wu,%20Hongbin&rft.date=2021-12-01&rft.volume=193&rft.issue=12&rft.spage=3867&rft.epage=3876&rft.pages=3867-3876&rft.issn=0273-2289&rft.eissn=1559-0291&rft_id=info:doi/10.1007/s12010-021-03664-z&rft_dat=%3Cproquest_cross%3E2601154852%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2601154852&rft_id=info:pmid/34524633&rfr_iscdi=true |